Medable vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Medable raised $304M to build the leading decentralized clinical trial (DCT) platform, enabling remote patient participation, eConsent, and wearable data integration for pharmaceutical trials.
About
Medable provides the technology infrastructure for decentralized clinical trials (DCTs) — enabling pharmaceutical companies to conduct trials where patients participate from home rather than traveling to research sites. The platform covers the full DCT workflow: electronic informed consent (eConsent), remote patient monitoring via wearables, telemedicine visits, electronic clinical outcome assessments (eCOA), and direct-to-patient drug delivery coordination.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.